1. Home
  2. WINT vs AKAN Comparison

WINT vs AKAN Comparison

Compare WINT & AKAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • WINT
  • AKAN
  • Stock Information
  • Founded
  • WINT 1992
  • AKAN 2021
  • Country
  • WINT United States
  • AKAN United Kingdom
  • Employees
  • WINT N/A
  • AKAN N/A
  • Industry
  • WINT Biotechnology: Biological Products (No Diagnostic Substances)
  • AKAN Medicinal Chemicals and Botanical Products
  • Sector
  • WINT Health Care
  • AKAN Health Care
  • Exchange
  • WINT Nasdaq
  • AKAN Nasdaq
  • Market Cap
  • WINT 2.0M
  • AKAN 2.3M
  • IPO Year
  • WINT 1995
  • AKAN 2022
  • Fundamental
  • Price
  • WINT $0.12
  • AKAN $1.72
  • Analyst Decision
  • WINT Hold
  • AKAN
  • Analyst Count
  • WINT 1
  • AKAN 0
  • Target Price
  • WINT $7.00
  • AKAN N/A
  • AVG Volume (30 Days)
  • WINT 7.3M
  • AKAN 81.3K
  • Earning Date
  • WINT 11-27-2024
  • AKAN 02-14-2025
  • Dividend Yield
  • WINT N/A
  • AKAN N/A
  • EPS Growth
  • WINT N/A
  • AKAN N/A
  • EPS
  • WINT N/A
  • AKAN N/A
  • Revenue
  • WINT N/A
  • AKAN $2,508,317.00
  • Revenue This Year
  • WINT N/A
  • AKAN N/A
  • Revenue Next Year
  • WINT N/A
  • AKAN N/A
  • P/E Ratio
  • WINT N/A
  • AKAN N/A
  • Revenue Growth
  • WINT N/A
  • AKAN N/A
  • 52 Week Low
  • WINT $0.11
  • AKAN $1.22
  • 52 Week High
  • WINT $14.75
  • AKAN $47.52
  • Technical
  • Relative Strength Index (RSI)
  • WINT 15.60
  • AKAN 55.45
  • Support Level
  • WINT $0.21
  • AKAN $1.46
  • Resistance Level
  • WINT $0.33
  • AKAN $1.70
  • Average True Range (ATR)
  • WINT 0.03
  • AKAN 0.13
  • MACD
  • WINT 0.00
  • AKAN -0.00
  • Stochastic Oscillator
  • WINT 2.15
  • AKAN 59.30

About WINT Windtree Therapeutics Inc.

Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.

About AKAN Akanda Corp.

Akanda Corp is a cannabis cultivation, manufacturing, and distribution company. The Company has three reportable segments: Cultivation, Distribution, and Corporate. Cultivating activities comprise the cultivation segment made up of the medical cannabis cultivation operations at RPK/Holigen in Portugal, and medical cannabis cultivation activities. Distributing activities relate to the distribution of medical cannabis by Canmart Ltd in the United Kingdom. Corporate activities entail head office costs and other general corporate expenses related to the administration of the broader group.

Share on Social Networks: